Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan. A phase II trial of the Puget Sound Oncology Consortium

Gynecologic Oncology

Volumn 110, Issue 2, 2008, Pages 146-151

  Goff, Barbara A ^a   Holmberg, Leona A ^a   Veljovich, Dan ^b   Kurland, Brenda F ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Pacific Gynecology Specialists   (United States)

^c USA   (United States)

Author keywords

Gemcitabine; Ovarian cancer; Platinum resistant; Topotecan

Indexed keywords

GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PLATINUM DERIVATIVE; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANXIETY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LIVER TOXICITY; LUNG DISEASE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGICAL COMPLICATION; NEUTROPENIA; OVARY CANCER; PAIN; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE TUBE TUMOR; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FALLOPIAN TUBE NEOPLASMS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; QUALITY OF LIFE; TOPOTECAN;

EID: 47249089925     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.04.037     Document Type: Article

References (26)

1. McGDuire W.P. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. NEJM 16 (1996) 1070
2. Lund B., Kristajansen P.E., and Hansen H.H. Clinical and preclinical activity of 2′, 2′ diflurorodeoxy-cytidine (gemcitabine). Cancer Treat Rev 19 (1993) 45-55
3. Lund B., Hansen O.P., Theilade K., Hansen M., and Neijt J.P. Phase II study of gemcitabine (2′,2′ difurorodeoxy-cytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86 (1994) 1530-1533
4. Underhill C., Parnis F.X., Highley M., Ahern J., Lung B., Domberknowsky, et al. A phase I study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer (EOC). Proceedings of ASCO vol. 15 (March, 1996)
5. Hansen H.H., Eisenhauer E.A., Hansen M., Jeijt J.P., Piccart M.J., Sessa C., et al. New cytostatic drugs in ovarian cancer. Ann Oncol 4 (1993) S63-70
6. Goff B.A., Thompson T., Greer B.E., Jacobs A., and Storer B. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: a phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602). Am J Obstet Gynecol 188 6 (2003) 1556-1562 discussion 1562-4
7. Ten Bokkel Huinink W., Gore M., Carmichael J., et al. Hycamtin versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15 (1997) 2183-2193
8. Cremers G.H., Bolis G., Gore M., et al. Hycamtin, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14 (1996) 3056-3061
9. Bookman M.A., Malmström H., Bolis G., et al. Hycamtin for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treatment after prior chemotherapy containing cisplatin or carboplatin and paclitaxel. J Clin Oncol 16 (1998) 3345-3352
10. Homesley H.D., Hall D.J., Martin D.A., et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 83 (2001) 394-399
11. Dabrow M.D., Francesco M.R., Gilman P.B., and Meyer T.J. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer. Proc Annual Meeting Am Soc Clin Oncol 18 (1999) A1930
12. Sun W., Stevenson J.P., Gallagher M., et al. A phase I trial of topotecan and gemcitabine administered weekly for three consecutive weeks to patients with advanced tumors. Cancer 92 2 (2001) 414-419
13. Greggi S., Salerno M.G., D'Agostino G., et al. Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology 60 1 (2001) 19-23
14. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 3 (2000) 205-216
15. Cella D.F., Tulsky D.S., Gray G., Sarafian B., Linn B., Bonomi A., et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Cln Oncol 11 (1993) 570-579
16. Basen-Enquist K., Bodurka-Bevers D., Fitzgerald M.A., Webster K., Cella D., Hu S., et al. Reliability and validity of the functional assessment of cancer therapy-ovarian (FACT-O). J Clin Oncol 19 6 (2001) 1809-1817
17. Liang K.Y., and Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 7 (1986) 13-22
18. Ozols R.F., Rubin S.C., Thomas G.M., and Robboy S.J. Epithelial ovarian cancer. In: Hoskins W.J., Perez C.A., Young R.C., Barakat R.R., Markan M., and Randall M.E. (Eds). Principles and practice of gynecologic oncology (2005), Lippincott Williams 895-988
19. Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacvae A.J., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 29 (2006) 4699-4707
20. D'Agostio G., Amant F., Berteloot P., Scambia G., and Vergote I. Phase II study of gemcitabine in recurrent platinum and paclitaxel-resistant ovarian cancer. Gynecol Oncol 88 3 (2003) 266-269
21. Markman M., Webster K., Zanotti K., Kulp B., Peterson G., and Belinson J. Phase II trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 90 3 (2003) 593-596
22. Sehouli J., Stengel D., Oskay G., Blohmer J., Kaubitzsch S., and Lichtenegger W. A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum. J Obstet Gynaecol Res 29 3 (2003) 123-131
23. Sehouli J., Stengel D., Oskay G., Camara O., Hindenburg H.J., Klare P., et al. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Ann Oncol 13 11 (2002) 1749-1755
24. Chen M.D., Fleming G.F., Mitchell S., and Horowitz I. A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 100 1 (2006) 111-115
25. Dabrow M.B., Francesco M.R., Gilman P.B., Cantor R., Rose L., and Meyer T.J. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer. Cancer Investig 21 (2003) 512-517
26. Distefano M., Ferlini C., De Vincenzo R., et al. Antagonistic effect of the combination of gemcitabine/topotecan in ovarian cancer cells. Oncol Res 121 (2000) 355-359